anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Daptomycin is an antibiotic with Gram-positive activity, including methicillin-resistant Staphylococcus aureus, for which optimal pediatric dosing is unknown. This study aimed to evaluate daptomycin exposures achieved with package label dosing and to identify dosing regimens necessary to enhance efficacy and minimize toxicity in children with S. aureus bacteremia. Monte Carlo simulations were performed to determine probability of target attainment (PTA) for six pediatric age cohorts. Area under the curve to minimum inhibitory concentration ratio (AUC0-24:MIC) ≥666 was used to determine the PTA for efficacy (PTAE). Minimum concentration (Cmin) ≥24.3 mg/L determined the PTA for toxicity (PTAT). Acceptable dosing regimens were those which achieved the combined target of ≥90% PTAE and ≤5% PTAT. Package label dosing of daptomycin yielded insufficient efficacy with only 26.3% PTAE in children 13-24 months, 39.5% PTAE in children 2-6 years, 30.1% PTAE in children 7-11 years, and 50.1% PTAE in adolescents ≥12 years. To achieve the combined efficacy and safety target, doses of 18-24 mg/kg in children 3-12 months, 20-24 mg/kg in children 13-24 months, 19-24 mg/kg in children 2-6 years, 17-19 mg/kg in children 7-11 years, and 10-14 mg/kg in adolescents ≥12 years are necessary. Package label dosing resulted in suboptimal exposure for the majority of pediatric patients in all age groups evaluated. If targeting validated efficacy and safety endpoints, daily daptomycin doses of at least 20 mg/kg in children ≤6 years, 17 mg/kg in children 7-11 years, and 10 mg/kg in adolescents ≥12 years are necessary. Clinical studies evaluating these higher doses are needed.
<P>PROBLEM TO BE SOLVED: To provide an uricosuric agent, and to provide foods and drinks, medicines and cosmetics containing the agent.  <P>SOLUTION: (1) The uricosuric agent containing ellagic acid as an active ingredient is provided. (2) The uricosuric agent containing Punica granatum L. extracts as active ingredients is provided. (3) Foods and drinks, medicines and cosmetics containing a uricosuric agent of (1) or (2) described above are provided. (4) Foods and drinks, labeled with that they contain the ellagic acid or the Punica granatum L. extracts and are usable for uricosuric promotion, are provided. The ellagic acid and the Punica granatum L. extracts have uricosuric action and, as a uricosuric agent, are useful for decrease of blood uric acid value, a hyperuricemia preventing and improving agents, and prevention of gout.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention discloses a traditional Chinese medicine composition which comprises, by mass, 4-6 parts of omphalia, 10-12 parts of cyrtomium fortunei, 6-8 parts of carpesium, 5-7 parts of rangoon creeper fruit, 6-8 parts of radix stemonae, 7-10 parts of rheum officinale, 3-8 parts of betel nut, 4-10 parts of pharbitis seed, 1-3 parts of chinaberry fruit, 4-5 parts of costustoot, 1-3 parts of agilawood, 6-8 parts of dark plum fruit and 5-6 parts of myrobalan. The Omphalia, cyrtomium rhizome, common carpesium fruit, rangooncreeper fruit and stemona root in the composition have the function of expelling and killing gastrointestinal parasites and are monarch drugs. Purging radix et rhizoma Rhei to expel parasites; betel nut and semen Pharbitidis have the effects of killing parasites and eliminating stagnation, and descending qi and promoting the circulation of qi; the chinaberry fruit is used as a ministerial drug for killing pests, soothing the liver and relieving pain. Mu Xiang can regulate qi to alleviate pain, Chen Xiang can promote qi circulation and warm middle energizer, and is used as adjuvant drug. Chebulae fruit, fructus Chebulae astringes lung qi and intestines to check diarrhea, is used as guiding drug. When used together, it has the functions of repelling, killing and expelling pests.
Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. In short-term schizophrenia adult trials, syncope was reported in 0.2% (1/572) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0.3% (1/378) of patients treated with placebo. In short-term bipolar mania adult trials, syncope was reported in 0.2% (1/620) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0% (0/329) of patients treated with placebo. During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, syncope was reported in 0.6% (11/1953) of patients treated with SAPHRIS. In a 3-week, bipolar mania pediatric trial, syncope was reported in 1% (1/104) of patients treated with SAPHRIS 2.5 mg twice daily, 1% (1/99) of patients treated with SAPHRIS 5 mg twice daily, and 0% (0/99) for patients treated with SAPHRIS 10 mg twice daily compared to 0% (0/101) for patients treated with placebo.

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients with cerebrovascular disease. SAPHRIS should be used cautiously when treating patients who receive treatment with other drugs that can induce hypotension, bradycardia, respiratory or central nervous system depression [see Drug Interactions (7.1)]. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs.
Doxorubicin (DOX) is an effective anticancer agent, but its clinical utility is constrained by dose-dependent cardiotoxicity, partly due to cardiomyocyte ferroptosis. However, the progress of developing cardioprotective medications to counteract ferroptosis has encountered obstacles. Protosappanin A (PrA), an anti-inflammatory compound derived from hematoxylin, shows potential against DOX-induced cardiomyopathy (DIC). Here, it is reported that PrA alleviates myocardial damage and dysfunction by reducing DOX-induced ferroptosis and maintaining mitochondrial homeostasis. Subsequently, the molecular target of PrA through proteome microarray, molecular docking, and dynamics simulation is identified. Mechanistically, PrA physically binds with ferroptosis-related proteins acyl-CoA synthetase long-chain family member 4 (ACSL4) and ferritin heavy chain 1 (FTH1), ultimately inhibiting ACSL4 phosphorylation and subsequent phospholipid peroxidation, while also preventing FTH1 autophagic degradation and subsequent release of ferrous ions (Fe2+) release. Given the critical role of ferroptosis in the pathogenesis of ischemia-reperfusion (IR) injury, this further investigation posits that PrA can confer a protective effect against IR-induced cardiac damage by inhibiting ferroptosis. Overall, a novel pharmacological inhibitor is unveiled that targets ferroptosis and uncover a dual-regulated mechanism for cardiomyocyte ferroptosis in DIC, highlighting additional therapeutic options for chemodrug-induced cardiotoxicity and ferroptosis-triggered disorders.
PURPOSE:A chewing gum, obtained by adding a saccharide raw material and perfume to a gum base raw material, and incorporating a polishing agent and medicinal component, and capable of giving tooth cleaning effect by chewing. CONSTITUTION:A chewing gum obtained by adding a saccharide raw material, e.g. cane sugar, and perfume, e.g. peppermint oil, to a gum base raw material, e.g. Mexican chicle, and incorporating a polishing agent, e.g. calcium hydrogenphosphate or silicic acid anhydride, having not so high hardness, fine particle size without sharp shape without fear of damaging teeth or wounding gingival tissue and a medicinal component therewith. The staining of teeth is removed by the polishing agent, and gingivitis is prevented and treated by the medicinal component.
Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
Technetium Tc 99m decays by isomeric transition with a physical half-life of 6 hours. The principal photon that is useful for detection and imaging studies is listed in Table 7.

The air-kerma-rate (exposure-rate) constant for Technetium Tc 99m is 5.23 m2·pGy·(MBq)−1·s−1 [0.795 cm2·R·(mCi)−1·h−1]. A range of values for the relative radiation attenuation by the various thicknesses of lead is shown in Table 8. For example, the use of a 3 mm thickness of lead will attenuate the radiation emitted by a factor of about 1,000.

To correct for physical decay of this radionuclide, the fractions that remain at selected intervals after the time of calibration are shown in Table 9.
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Over 1,900 mutations, categorized into five genotypic or functional classes are implicated in causing CF. Severity of disease varies widely in CF based on CFTR-dependent and independent factors. Progressive obstructive lung disease is the main determinant of morbidity and mortality in CF; therefore it is critical to identify biomarker profiles that reflect and predict this phenotypic variability, and understand their relationship to residual CFTR activity. Emerging CFTR modulator therapies that directly target defective CFTR are being evaluated in pivotal clinical trials and may become available in the next few years. It is not known how partial restoration of CFTR function might impact CF disease progression and disease-related biomarkers. Thus there is urgent need to i) identify and validate biomarkers that might reflect partial restoration of CFTR function and can be used to monitor disease progression, and ii) evaluate the mechanistic effects of CFTR modulators and other relevant therapies in individuals with CF
The invention relates to a method for producing unsaturated fatty acids comprising at least two double bonds, and a method for producing triglycerides having an increased content of polyunsaturated fatty acids comprising at least two double bonds. The invention also relates to the advantageous use of the nucleic acid sequences of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 18 in the inventive methods, and for producing a transgenic organism, preferably a transgenic plant or a transgenic micro-organism having an increased content of fatty acids, oils or lipids containing unsaturated C18, C20, or C22 fatty acids. The invention further relates to novel desaturases comprising the sequences of SEQ ID NO. 1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 11, or the homologues, derivatives or analogues thereof, and gene constructs comprising said genes or the homologues, derivatives or analogues thereof, in addition to the use of the same, either alone or combined with biosynthesis genes of polyunsaturated fatty acids, as advantageously represented in SEQ ID NO: 7 and SEQ ID NO: 9. Furthermore, the invention relates to isolated nucleic acid sequences, expression cassettes containing said nucleic acid sequences, vectors, and transgenic organisms containing at least one nucleic acid sequence or an expression cassette. The invention also relates to unsaturated fatty acids comprising at least two double bonds and triglycerides having an increased content of unsaturated fatty acids comprising at least two double bonds, and the use of the same. Finally, the invention relates to multi-expression cassettes for seed-specific expression, in addition to vectors or organisms comprising a desaturase gene, either alone or combined with other desaturases having the sequence of SEQ ID NO: 7 and/or elongase genes having the sequence of ID NO: 9 or the homologues, derivatives or analogues of the same, expressed by means of the above-mentioned expression cassettes.
The invention relates to a traditional Chinese medicine for treating unrecognized pyogenic infections. The traditional Chinese medicine is characterized by being prepared from the following raw medicinal medicines in parts by weight: 4 parts of gynura japonica, 3 parts of coriandrum sativum, 3 parts of roots of gaultheria yunnanensis, 1 part of ajuga pantantha hand.-Mazz, 5 parts of aralia decaisneana hance, 1 part of folium picrasmae quassioidis, 6 parts of Aucuba himalaica Hook f.et Thoms., 5 parts of Sabina chinensis (L.) Ant.[Juiperus chinensis.L.], 2 parts of horse bone, 2 parts of twig and leaf of eriocarpous glochidion, 5 parts of radix gentianae macrophyllae, 3 parts of liparis odorata (Willd.) Lindl, 2 parts of nidus vespae, 2 parts of euphorbia lunulata, 3 parts of santalum album, 4 parts of cacumen biotae, 4 parts of amur corktree bark and 3 parts of zedoray rhizome. Clinical experiments prove that the traditional Chinese medicine can treat unrecognized pyogenic infections safely and effectively.
There is a subgroup of nAMD patient requiring monthly interventions, when applying as needed and treat-and-extend treatment strategies. A burden for both patient/caregivers and health care systems. More durable treatment options are needed to increase the quality of life for these nAMD patients, as well as to make human resources available for the growing elderly AMD population requiring treatment.

The FAN study is a randomized, double-masked, 2-arm (comparator-controlled), phase-IV, monocenter study with a primary endpoint at 32 weeks. The study is conducted into 2 parts. Patients will receive either aflibercept or faricimab via treat-and-extend principle until the primary endpoint (part 1). As mentioned, the main objective is to assess the durability of both drugs in this particular subgroup of nAMD patients. In part 2 of the study, starting at or after 32 weeks, all patients will receive faricimab via treat-and-extend until the end of the study (56 weeks).
Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 \& 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
Endoscopic resection (ER) of esophageal squamous cell carcinoma (ESCC) is evaluated pathologically, and additional treatment is recommended for cases resulting in non-curative resection, defined as pMM with lymphovascular invasion (LVI), pSM, or positive vertical margin. This study aimed to assess long-term outcomes and risk factors for recurrence in patients with ESCC treated with non-curative ER followed by additional chemoradiotherapy (CRT). We retrospectively reviewed the clinical courses of patients who underwent non-curative ER followed by additional CRT for ESCCs between August 2007 and December 2017. Recurrence rates and risk factors for recurrence were analyzed. Among 97 patients with non-curative ER, 73 underwent additional CRT. With a median follow-up period of 71 months, recurrences were observed in 10 (14%) of 73 patients, with a median interval of 24.5 (1-59 months). The 3- and 5-year recurrence-free survival were 89 and 85%, respectively, and the 3- and 5-year overall survival rates were 96 and 91%, respectively. Multivariate analysis showed that lymphatic invasion was an independent risk factor for recurrence in patients with non-curative ESCC receiving additional CRT. Among the 10 patients with recurrence, 4, 3, 2, and 1 underwent surgery, chemotherapy, supportive care, and CRT, respectively. Notably, all four patients who underwent surgery survived, regardless of regional and/or distant lymph node metastasis. Lymphatic invasion is an independent risk factor for the recurrence of non-curative ESCCs. Careful follow-up is required for at least 5 years after ER with additional CRT.
BACKGROUND: Recent anatomic and electrophysiologic evidence has provided new insight into the anatomic substrate. Previous reports on electroanatomic mapping (EAM) of the circuit of atrioventricular nodal reentrant tachycardia (AVNRT) have been limited by mapping only the triangle of Koch on the right side of the septum and by the use of conventional mapping tools. The objectives are to obtain comprehensive high-resolution mapping of typical AVNRT and to investigate the role of the atrioventricular ring tissues in the circuit.
METHODS: We employed EAM with the use of novel modules and algorithms for studying typical AVNRT from the right and the left sides of the septum.
RESULTS: We performed extensive mapping of both the atrial septum and the septal vestibule of the tricuspid valve during typical AVNRT in 9 (6 females) patients, aged 49.6 ± 12.1 years. In two of these, left septal mapping was also obtained through the aorta. The earliest initial activation was variable, emanating from the superior or medial septum. The impulse consistently appeared below the orifice of the coronary sinus, at the site where its inferoanterior margin merged with the septal vestibule of the tricuspid valve at its entrance to the right atrium. It then returned to the initial activation site, presumably through the septal vestibular myocardium. The left septal activation area corresponded to that recorded on the right side.
CONCLUSIONS: Typical AVNRT uses a circuit confined within the pyramid of Koch from the AV node to the septal isthmus, involving the myocardial walls of the pyramidal space.
A carrier for delivering at least one active principle at an intraluminal site. The carrier includes a carrier body, such as a stent. The carrier body is provided with one or more reservoirs. The reservoirs contain nanoparticles which convey at least one active principle. The nanoparticles also comprise a substance having characteristics of preferential affinity attraction to a desired region at the intraluminal site. The nanoparticles can migrate toward the preferred region.
PURPOSE:The titled gel ointment, obtained by incorporating a vidarabin with a local anesthesia, carboxyvinyl polymer which is a viscosity increasing agent, lower alcohol, neutralizing agent and water in a specific proprtion, readily handleable and having improved feeling of use, drug effect on herpes zoster, etc. CONSTITUTION:A vidarabin gel ointment obtained by incorporating 0.05-1wt% (expressed in terms of vidarabin) vidarabin expressed by the formula with 0-10wt% local anethesia, 0.1-5wt% carboxyvinyl polymer, 5-30wt% wetting agent, e.g. PEG, 5-50wt% 1-3C lower alcohol, neutralizing agent for adjusting pH and water in an adequate amount. The ointment is characterized in that the carboxyvinyl polymer is used as the gelling and viscosity increasing agent. The oingment has more improved feeling of use and percutaneous absorbability than the conventional oily ointment, and can be effectively used for local diseases, e.g. herpes zoster, labial herpes, etc., with good storage stability.
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including naproxen, a component of VIMOVO. Hepatic abnormalities may be the result of hypersensitivity rather than direct toxicity. These laboratory abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. The SGPT (ALT) test is probably the most sensitive indicator of liver dysfunction. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with VIMOVO. 

If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, eosinophilia, rash, etc.), VIMOVO should be discontinued. 

Chronic alcoholic liver disease and probably other diseases with decreased or abnormal plasma proteins (albumin) reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. Caution is advised when high doses are required and some adjustment of dosage may be required in these patients. It is prudent to use the lowest effective dose for the shortest possible duration of adequate treatment.

VIMOVO should be avoided in patients with severe hepatic impairment [see Dosage and Administration (2), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
FIELD: microbiology. SUBSTANCE: preparing strain C. pseudotuberculosis ВГНКИ N 74 R-ДЕП for identification acceleration of cavernous lymphadenitis pathogen in sheep at bacteriological, allergic and serological diagnosis. Molecular properties of strain DNA: spectral indices: A 260/280 = 2.0, A 260/230 = 2.2, concentration - 1200 mcg/ml, melting point is 33.5 C, content of G + C = 47.8 mole%. On the basis of homology of DNA nucleotide sequence strain is concerned to the group III. For disease diagnosis allergen is administrated to sheep by intracutaneous route into subtail wrincle which is prepared from this strain. Reaction recording is carried out after 24 hr. In sick animal inflammatory reaction appeared in the place of diagnosticum administration. No inflammation in health animals. Method ensures to detect additionally up to 80% infected animals as compared with conventional method of diagnosis (by palpation of surface lymphatic nodes). EFFECT: accelerated identification of pathogen.
<P>PROBLEM TO BE SOLVED: To produce a material containing sphingoglycolipid in a high concentration and used for a beverage and foods efficiently and industrially by using plant materials (rice bran, wheat bran, beat fiber, konjak powder, etc.) as raw materials.  <P>SOLUTION: This method for producing the sphingoglycolipid is provided by subjecting the plant materials to extraction with ethanol, freeze-treating the separated ethanol solution (storing at ≤-50°C for ≥12 hr) and obtaining the sphingoglycolipid-containing material as precipitate. By the method, e.g. in the case of using the beat fiber, it is possible to obtain the sphingoglycolipid-containing material having ≥50 % sphingoglycolipid content.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
With a composition of natural products without chemical additions such as: boiler basis cream, sesame oil, carrot oil, wheat germ oil, olive oil, almond oil, jojoba oil, ylang-ylang, anti-wrinkle cream. These aforementioned oils are ethereal oils. It is a yellow liquid cream. It is a completely new formula. It is specially composed in order to obtain a 5x quicker facial tanning with a little sun or a sun bed without wrinkle formation. The skin moisturisation is optimal due to the essential oils and ageing of the skin is reduced. Absorbs immediately in the skin and does not leave skin feeling greasy. Has not been tested on animals. Makes the skin feel silky smooth. Is extremely effective for application before sunning, after sunning before the sun bed and after the sun bed and also as an after-sun. Is very effective and has a pleasant scent.